Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Follow-up after treatment of gestational trophoblastic disease

After mole evacuation

  • Serum hCG is monitored every other week until <1 IE/L for three repeated measurements. Serum hCG is then checked monthly for 6 months.
  • Birth control is recommended during the entire follow-up period after hcg is normalized (<1IE/L). Options include birth control pills, IUD or barrier method, or sterilization.

After chemotherapy for gestational trophoblastic disease

Serum hCG is checked:

  • before start of each course
  • weekly the first 3 months after treatment
  • every other week from 3-6 months after treatment
  • monthly from 6-12 months after treatment

Low risk patients do not need follow-up after one year. It is recommended the patient should use effective birth control for one year until after the first normal hCG (<1IE/L) measurement.

High risk patients have hCG testing as described above for 12 months, thereafter every 3 months for an additional 12 months. The patient is recommended to use effective birth control for 24 months after the first normal measurement of hCG.

Patients with placental-site trophoblastic tumors have hCG testing as described above for the first 2 years, then every 6 months for 5-10 years. Thereafter, the patient will have annual follow-up for life due to the risk for late recurrence. 

Pregnancy after gestational trophoblastic disease

Patients with normal hCG 8 weeks after evacuation are discouraged from becoming pregnant during the first 6 months. 

Patients with raised hCG 8 weeks after evacuation are discouraged from becoming pregnant during the first 12 months.

Pregnancy during the follow-up period often has a normal outcome. It is important the patient has follow-up with repeated hCG testing and early ultrasound to exclude a possible new molar pregnancy. New trophoblastic disease at the next pregnancy is rare, but may occur. For pregnancy after trophoblastic disease, a vaginal ultrasound should be performed early in the pregnancy. After the birth, the placental should be carefully inspected and sent for a histological examination.

Complications related to the disease:

  • Tumor bleeding
  • Uterine bleeding
  • Brain hemorrhaging
  • Hemoptysis

Complications related to treatment

  • Uterine perforation during evacuation/biopsy.

  • Respiratory insufficiency at the start of treatment in a patient with visible lung metastases.
  • Brain hemorrhage at the start of treatment of brain metastases.
  • Kidney, liver, and neurotoxicity from methotrexate.
  • Consider listing toxicities associated with EMA-CO. 

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018